Steve Kelsey, M.D., President of Research and Development, announced his intent to retire effective January 4, 2027. He will transition to senior advisor to the CEO on July 1, 2026, and the company intends to appoint him to the board of directors upon his retirement, subject to approval. The company also reported results from its June 18, 2026 annual meeting, where stockholders elected Alexis Borisy and Mark A. Goldsmith as Class III directors, ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026, and approved executive compensation on an advisory basis. Revolution Medicines is a clinical-stage biopharmaceutical company that develops targeted therapies for cancer.